IMATINIB TABLETS IP 100 mg & 400 mg — PAS NIB

Product Overview — IMATINIB TABLETS IP (PAS NIB)

PAS NIB (Imatinib Tablets IP 100 mg & 400 mg) is a targeted anticancer therapy belonging to the class of tyrosine kinase inhibitors. It selectively inhibits abnormal proteins responsible for uncontrolled cancer cell growth, particularly the BCR-ABL tyrosine kinase.

PAS NIB plays a critical role in the treatment of hematological malignancies and solid tumors by blocking signals that stimulate cancer cell proliferation and survival.

  • Available Strengths: 100 mg & 400 mg
  • Dosage Form: Film-coated tablets
  • Schedule: Schedule H Drug
  • Usage: For Registered Medical Practitioner / Hospital use only
  • Marketed by: PAS NIB
  • Manufacturing: WHO-GMP Certified Facility (India)
PAS NIB Imatinib Tablets IP 100 mg and 400 mg blister pack

Therapeutic Indications of PAS NIB

  • Newly diagnosed Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML).
  • CML in chronic phase after interferon-alpha failure.
  • CML in accelerated phase or blast crisis.
  • Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
  • Unresectable, metastatic, or recurrent Gastrointestinal Stromal Tumors (GIST).
  • Myelodysplastic / Myeloproliferative diseases associated with PDGFR rearrangements.
  • Aggressive systemic mastocytosis (without D816V mutation).
  • Hypereosinophilic syndrome (HES).
  • Dermatofibrosarcoma protuberans (DFSP).

Dosage & Administration of PAS NIB

PAS NIB should be taken orally once daily with a meal and a large glass of water to minimize gastrointestinal irritation.

  • CML (Chronic Phase): 400 mg once daily
  • CML (Accelerated / Blast Crisis): 600–800 mg daily
  • Ph+ ALL: 600 mg daily
  • GIST: 400 mg daily (may increase to 800 mg)

Dose adjustment may be required in patients with hepatic or renal impairment and should be decided strictly by the treating oncologist.

PAS NIB Imatinib Tablets dosage and administration

Safety Information & Warnings — PAS NIB

Common adverse reactions include nausea, vomiting, diarrhea, edema, muscle cramps, fatigue, myelosuppression, rash, hepatotoxicity, and fluid retention.

PAS NIB interacts with CYP3A4 inhibitors/inducers, warfarin, acetaminophen, and drugs affecting liver enzymes. Close monitoring is required.

Contraindicated in patients with hypersensitivity to imatinib or excipients. Use during pregnancy may cause fetal harm.

Storage & Packaging of PAS NIB

Store PAS NIB tablets below 30°C, protected from moisture and light.

Keep out of reach of children.

Shelf Life: As per label instructions.

Legal Status: Schedule H Drug — Prescription only.

Usage Restriction: For hospital / RMP use only.

PAS NIB Imatinib Tablets IP packaging